Immunohistopathology and Steroid Profiles Associated With Biochemical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism

Unilateral primary aldosteronism (PA) is the most common surgically curable form of hypertension that must be accurately differentiated from bilateral PA for therapeutic management (surgical versus medical). Adrenalectomy results in biochemical cure (complete biochemical success) in almost all patients diagnosed with unilateral PA; the remaining patients with partial or absent biochemical success comprise those with persisting aldosteronism who were misdiagnosed as unilateral PA preoperatively. To identify determinants of postsurgical biochemical outcomes, we compared the adrenal histopathology and the peripheral venous steroid profiles of patients with partial and absent or complete biochemical success after adrenalectomy for unilateral PA. A large multicenter cohort of adrenals from patients with absent and partial biochemical success (n=43) displayed a higher prevalence of hyperplasia (49% versus 21%; P=0.004) and a lower prevalence of solitary functional adenoma (44% versus 79%; P<0.001) compared with adrenals from age- and sex-matched patients with PA with complete biochemical success (n=52). We measured the peripheral plasma steroid concentrations in a subgroup of these patients (n=43) and in a group of patients with bilateral PA (n=27). Steroid profiling was associated with histopathologic phenotypes (solitary functional adenoma, hyperplasia, and aldosterone-producing cell clusters) and classified patients according to biochemical outcome or diagnosis of bilateral PA. If validated, peripheral venous steroid profiling may be a useful tool to guide the decision to perform surgery based on expectations of biochemical outcome after the procedure.

[1]  M. Bäckdahl,et al.  Comprehensive Re-Sequencing of Adrenal Aldosterone Producing Lesions Reveal Three Somatic Mutations near the KCNJ5 Potassium Channel Selectivity Filter , 2012, PloS one.

[2]  Fiorenzo Gaita,et al.  Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. , 2018, The lancet. Diabetes & endocrinology.

[3]  Graeme Eisenhofer,et al.  Mass Spectrometry-Based Adrenal and Peripheral Venous Steroid Profiling for Subtyping Primary Aldosteronism. , 2016, Clinical chemistry.

[4]  R. Kuick,et al.  Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands , 2015, Proceedings of the National Academy of Sciences.

[5]  S. Ito,et al.  Measurement of Peripheral Plasma 18-Oxocortisol Can Discriminate Unilateral Adenoma From Bilateral Diseases in Patients With Primary Aldosteronism , 2015, Hypertension.

[6]  S. Tomlins,et al.  Aldosterone-Producing Cell Clusters in Normal and Pathological States , 2017, Hormone and Metabolic Research.

[7]  D. Nitti,et al.  Outcome of surgical treatment of primary aldosteronism , 2015, Langenbeck's Archives of Surgery.

[8]  A. Buck,et al.  Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma , 2018, Hypertension.

[9]  H. Sasano,et al.  Development of monoclonal antibodies against human CYP11B1 and CYP11B2 , 2014, Molecular and Cellular Endocrinology.

[10]  M. Stowasser,et al.  Success of Surgery for Primary Aldosteronism Judged by Residual Autonomous Aldosterone Production , 1998, World Journal of Surgery.

[11]  M. Suematsu,et al.  Case Report: Nodule Development From Subcapsular Aldosterone-Producing Cell Clusters Causes Hyperaldosteronism. , 2016, The Journal of clinical endocrinology and metabolism.

[12]  A. Fassina,et al.  Unilateral adrenal hyperplasia: a novel cause of surgically correctable primary hyperaldosteronism. , 2012, Surgery.

[13]  C. Gomez-Sanchez,et al.  Progress in Primary Aldosteronism: Present Challenges and Perspectives , 2010, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[14]  K. Nakagawa,et al.  Adrenocortical zonation in humans under normal and pathological conditions. , 2010, The Journal of clinical endocrinology and metabolism.

[15]  B. Tops,et al.  Adrenal nodularity and somatic mutations in primary aldosteronism: one node is the culprit? , 2014, The Journal of clinical endocrinology and metabolism.

[16]  Graeme Eisenhofer,et al.  Genotype-Specific Steroid Profiles Associated With Aldosterone-Producing Adenomas , 2016, Hypertension.

[17]  C. Gomez-Sanchez,et al.  Immunohistochemistry of the adrenal in primary aldosteronism , 2016, Current opinion in endocrinology, diabetes, and obesity.

[18]  M. Oya,et al.  Immunohistochemistry of aldosterone synthase leads the way to the pathogenesis of primary aldosteronism , 2017, Molecular and Cellular Endocrinology.

[19]  Saskia,et al.  Targeting CXCR 4 ( CXC Chemokine Receptor Type 4 ) for Molecular Imaging of Aldosterone-Producing Adenoma , 2022 .

[20]  F. Nwariaku,et al.  Contralateral adrenal abnormalities in Conn's syndrome. , 2016, The Journal of surgical research.

[21]  Pierre-François Plouin,et al.  Adrenal Cortex Remodeling and Functional Zona Glomerulosa Hyperplasia in Primary Aldosteronism , 2010, Hypertension.

[22]  M. Novello,et al.  Long-term renal outcomes in patients with primary aldosteronism. , 2006, JAMA.

[23]  W. Young,et al.  The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. , 2016, The Journal of clinical endocrinology and metabolism.

[24]  W. Young,et al.  Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. , 2017, The lancet. Diabetes & endocrinology.

[25]  W. Young,et al.  A Novel CYP11B2-Specific Imaging Agent for Detection of Unilateral Subtypes of Primary Aldosteronism. , 2016, The Journal of clinical endocrinology and metabolism.

[26]  C. Gomez-Sanchez,et al.  Disordered CYP11B2 Expression in Primary Aldosteronism , 2017, Hormone and Metabolic Research.

[27]  M. Suematsu,et al.  Disorganized Steroidogenesis in Adrenocortical Carcinoma, a Case Study , 2017, Endocrine Pathology.

[28]  W. Young,et al.  Role for adrenal venous sampling in primary aldosteronism. , 2004, Surgery.

[29]  Jeroen J. Bax,et al.  2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.

[30]  T. Strom,et al.  Genetic Spectrum and Clinical Correlates of Somatic Mutations in Aldosterone-Producing Adenoma , 2014, Hypertension.

[31]  S. Tomlins,et al.  Histopathological Classification of Cross-Sectional Image–Negative Hyperaldosteronism , 2016, The Journal of clinical endocrinology and metabolism.

[32]  G. Johannsson,et al.  Systematic review of surgery and outcomes in patients with primary aldosteronism , 2015, The British journal of surgery.

[33]  Katsutoshi Takahashi,et al.  Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009. , 2011, Endocrine journal.

[34]  Piotr Ponikowski,et al.  2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, European heart journal.

[35]  F. Veglio,et al.  Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. , 2013, The Journal of clinical endocrinology and metabolism.

[36]  Morris J. Brown,et al.  Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas. , 2012, The Journal of clinical endocrinology and metabolism.

[37]  D. Schteingart Adrenal Cortex Remodeling and Functional Zona Glomerulosa Hyperplasia in Primary Aldosteronism , 2011 .